Horizon Space Acquisition II announces business combination agreement with SL Bio

Written by Emily J. Thompson, Senior Investment Analyst

Source: SeekingAlpha

Updated: May 12 2025

0mins

HSPT+1.24%

Should l Buy HSPT?

Source: SeekingAlpha

Business Combination Announcement: Horizon Space Acquisition II Corp. has entered into a definitive business combination agreement with SL Bio, a biomedical company focused on cellular and gene therapies for skin care and cancer recovery.
Leadership and Timeline: The combined entity, to be named SL Science Holding Limited, is expected to be listed on Nasdaq by late 2025, with William Wang as CEO, Johnson Lau as CFO, and Ethan Shen as CTO.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy HSPT?" and start using high-conviction signals backed by rigorous historical data.

HSPT

$10.6+Infinity%1D

Analyst Views on HSPT

About HSPT

Horizon Space Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region. It has not selected any target business for its initial business combination. The Company has neither engaged in any operations nor generated any revenues.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Horizon Space Acquisition II Corp. Updates on SL BIO Business Combination Process

4 days agoNewsfilter

Redemption Process Clarification: HSPT has clarified the redemption process for shareholders regarding the business combination with SL BIO, requiring instructions to the transfer agent by 5 PM ET on February 11, 2026, to ensure shares are redeemed if the business combination or extension proposals are implemented.
Meeting Confirmation: The business combination meeting is scheduled for 9 AM on February 12, 2026, with a redemption deadline of 5 PM on February 10, ensuring shareholders can participate in voting at the Robinson & Cole LLP office in New York.
Shareholder Voting Rights: Shareholders as of the record date of December 29, 2025, retain voting rights even if shares are sold afterward, encouraging those who have not yet voted to act promptly to ensure their voices are heard.
Risk Advisory: The company warns shareholders of potential risks, including the possibility of the merger not closing, emphasizing the importance of reviewing relevant documents to understand all details and implications of the merger.

SL BIO and HSPT Merger Approved by SEC, Expected Nasdaq Listing

Jan 14 2026Newsfilter

Merger Progress: The registration statement for the merger between SL BIO and HSPT was approved by the SEC on January 13, 2026, marking a significant step towards SL BIO becoming a public company, which is expected to enhance its financing capabilities and market influence.
Shareholder Meeting Scheduled: HSPT plans to hold a special shareholder meeting on February 3, 2026, to vote on the merger proposal, which, if approved, will pave the way for SL BIO's listing and further strengthen its competitive position in the biomedicine sector.
New Company Structure: Post-merger, SL Science Holding Limited will become the new holding company, expected to be listed on Nasdaq under the ticker symbol “SLBT,” providing SL BIO with broader access to capital markets to support its R&D and market expansion.
Innovative Technology Potential: SL BIO focuses on developing cellular and gene therapies using immune stem cells and bovine-derived milk exosomes, which are anticipated to drive breakthroughs in regenerative medicine and cancer treatment, presenting significant market prospects and strategic importance.

Saks Global Enterprises Faces Bankruptcy Risk, Seeks Capital Injection to Stay Afloat

Jan 09 2026Benzinga

Financial Crisis: Barely a year after acquiring Neiman Marcus for $2.65 billion, Saks Global Enterprises is facing potential bankruptcy, with lenders discussing capital injections to keep the luxury department store empire operational.
Supply Chain Issues: Vendors have begun slowing shipments due to Saks falling behind on payments, and the company’s request to extend overdue bills over a year has negatively impacted its reputation as a luxury retailer.
Acquisition Risks: Moody's has flagged the acquisition loans as highly risky, expressing doubts about the combined company's viability, which reflects market concerns regarding its future performance.
Strategic Challenges: Although the plan was to revive Saks and its brands through cost-cutting and tech upgrades, the actual execution has faced a crisis of trust with suppliers, potentially hindering future business recovery.

SL Bio to Merge with Horizon Space Acquisition II at $5.7 Billion Valuation, Plans 2026 Listing

Jan 09 2026Benzinga

Merger Overview: Taiwan-based SL Bio Ltd. has entered into a merger agreement with Horizon Space Acquisition II Corp, with an implied equity valuation of approximately $5.7 billion, marking a strategic shift for the company to enter the U.S. market via SPAC.
Listing Path Preference: This merger reflects the biotechnology sector's preference for SPAC transactions, particularly as traditional IPOs face challenges, enabling SL Bio to secure long-term capital and enhance market visibility.
Focus on R&D: SL Bio is concentrating on advanced cellular and gene therapy technologies, developing immunotherapies for high-need oncology indications such as blood cancers, pancreatic cancer, and brain tumors, showcasing its market potential in critical therapeutic areas.
Future Outlook: The combined entity is expected to go public in early 2026, and if successful, will provide U.S. investors with direct exposure to SL Bio, further enhancing its influence in the biotechnology sector.